Poniard Pharmaceuticals (PARD) Inactive 10-K2006 FY Annual report

Filed: 16 Mar 07, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	8th grade Avg

New words: accuracy, adhesion, Aeterna, analyst, antigen, antitakeover, API, Applera, ascribed, autoimmune, Avastin, award, bachelor, Bayer, Berkeley, bevacizumab, binomial, bioavailability, bulk, cap, capability, carefully, Carnegie, caroline, Celera, Cheni, College, colon, column, Comparison, CPISF, curve, Dainippon, database, deadly, departure, distinction, Eli, Eloxatin, embark, estramustine, experienced, fluorouracil, focal, FOLFOX, forfeiture, fractional, function, gave, Genentech, Genzyme, GLOBOCAN, GPC, Graduate, graph, harbor, Imperial, inaccuracy, inflammatory, ingredient, input, Insider, IRC, Keryx, Kwok, Lilly, loewy, London, Lynch, martell, Meabco, Mellon, men, Merrill, metropolitan, mild, mind, mixozantrone, moderate, modern, monotherapy, Morgan, muscle, neuropathy, nonpayment, Onyx, palliate, Pharma, Pharmion, point, poniard, preclincial, prednisone, prepayment, pricking, problem, procedure, Prudential, PSA, Ratification, refected, refocused, reinvested, reissuable, relocate, relocated, relocation, renegotiated, rental, repurchase, Reserved, reverse, ronald, scale, Schering, Secondary, Shionogi, Shoreline, SIC, Silicon, simon, SK, skin, solvency, South, SPEAR, split, Stanley, structure, subset, successor, Sumitomo, surgical, Sutent, Taxotere, technique, tenant, tingling, touch, Transave, unrecognized, unrestricted, Valley, Vion, women, Zeltia

Removed: advisor, alternate, amend, apply, assuming, attaining, BA, begin, Black, BS, calendar, called, coercive, commitment, comparing, consultant, declare, depreciated, designation, Diamond, Dina, discontinuing, dispensing, dissolution, DOTMP, earning, elapse, enable, encounter, enhanced, exclude, exercising, Extreme, filling, Findlay, focusing, govern, healthcare, identifying, involvement, Junior, Karen, Linda, line, location, mandatory, MD, methodology, monitoring, ninety, offered, offering, packaging, partnership, post, PPD, preference, preferential, promoted, purpose, qualification, ranged, ranging, rata, rated, reassigned, recalculated, redeem, register, repeal, retainer, settle, settlement, shipping, skeleton, steigrod, strong, substance, surrender, takeover, transplantation, TX, unfair, unit, utilization, utilizing, website, work

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

PARD similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

Certification of Annual Report

I, Caroline M. Loewy, Chief Financial Officer of Poniard Pharmaceuticals, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

1. the Annual Report on Form 10-K for the Company for the year ended December 31, 2006 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (12 U.S.C. 78m or 78o(d)); and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 15, 2007	By:	/s/ CAROLINE M. LOEWY
		Caroline M. Loewy Chief Financial Officer